DNA Sequencing Equipment and Services Markets, 3rd. Edition
This report, DNA Sequencing Equipment and Services Markets, represents the third time Kalorama has detailed the market for DNA sequencing systems, as well as consumables used in sequencing and sequencing services. Much has changed since the last Kalorama edition of this report. More companies are offering sequencing services. The market was moving in a relatively linear manner for about two years in terms of competition, with no disruptive technologies or business models introduced. After a period of relative stability, the market has seen major developments in 2011 and 2012. The introductions of the Ion Torrent PGM, PacBio RS and MiSeq have changed the situation in the market, with more new technologies expected from Ion Torrent as well as Oxford Nanopore.
DNA sequencing can be defined as any biochemical method for determining the order of the nucleotide bases, adenine, guanine, cytosine, and thymine, (A,G,C,T) in a DNA nucleotide. DNA Sequencing has accelerated research and discovery, which created a brisk market for sequencing systems that perform this work. TXThe growing availability of vast amounts of annotated sequence data permits life science researchers to undertake a much wider range of experiments.As part of the report’s coverage, the following data is provided:
The market remains volatile, but some patterns have been stabilizing in recent years. The report uses primary and secondary research to present market watchers with an assessment of the marketplace in 2012. As part of its coverage, the report profiles the following companies:
DNA sequencing can be defined as any biochemical method for determining the order of the nucleotide bases, adenine, guanine, cytosine, and thymine, (A,G,C,T) in a DNA nucleotide. DNA Sequencing has accelerated research and discovery, which created a brisk market for sequencing systems that perform this work. TXThe growing availability of vast amounts of annotated sequence data permits life science researchers to undertake a much wider range of experiments.As part of the report’s coverage, the following data is provided:
- Current Market Estimate
- Historical Market Data since 2006
- Forecast to 2016
- Review of Major Company Sequencing Products
- The Status of Next Gen Systems
- Clinical Applications vs. Research Applications in Sequencing
- Litigation and Intellectual Property Developments
- Deals in the Industry
- Market Share of Major Players
- Challenges and Strategic Recommendations
The market remains volatile, but some patterns have been stabilizing in recent years. The report uses primary and secondary research to present market watchers with an assessment of the marketplace in 2012. As part of its coverage, the report profiles the following companies:
- 454 Life Sciences (Roche)
- Complete Genomics
- Illumina
- Life Technologies
- Pacific Biosciences
CHAPTER ONE: EXECUTIVE SUMMARY
Introduction
New Systems, Services Create Uncertainty
A Period of Rapid Adoption, But Lower Prices
Further Longer-Term Challenges
Rapid Growth Overall, But Intense Competition
Customers’ Research Models Evolving
Established Next-Generation Systems Seeing Slowdown
Background
Scope and Methodology
Applications and Definitions
Types of Samples
DNA Sequencing Strategies
CHAPTER TWO: SEQUENCER MARKET TRENDS
Industry and Technology Trends
Market Fragmenting Into Multiple Product Types and Applications
Continual Improvements Expand Sequencer Market
Acquisitions and Collaborations for New Technologies
Patent Infringement, Other Legal Disputes
Slow Path to Potentially Large Clinical Markets
Spread of Targeted Enrichment, Sequence-Capture Products and Services
Synergies Appearing Between Life Science Companies’ Products
Consumer Genomics, Genetic Testing, Pharmacogenetics Still Entering Mainstream
NHGRI Funding, Budget, Periodic Strategic Planning
NHGRI Shifts Funds from Centralized Sequencing Centers
NHGRI White Paper #4: The Future of Genome Sequencing
Genome Projects and Consortia
The Cancer Genome Atlas (TCGA) Project
National Plant Genome Initiative
NSF/USDA Microbial Genome Sequencing Program
CHAPTER THREE: DNA SEQUENCING SYSTEMS AND TECHNOLOGIES
454 Life Sciences (Roche)
Genome Sequencer FLX, FLX+, Junior
Illumina
HiSeq, HiScan SQ, MiSeq, Genome Analyzer IIx
Intelligent Biosystems (Qiagen)/Azco Biotech
LI-COR Biosciences 4300
Life Technologies/Applied Biosystems
ABI Prism 310 Genetic Analyzer
ABI Prism 3100-Avant Genetic Analyzer
Applied Biosystems 3100 Genetic Analyzer
Applied Biosystems 3130 Genetic Analyzer
Applied Biosystems 3130xl Genetic Analyzer
Applied Biosystems 3500 Genetic Analyzer
Applied Biosystems 3730 DNA Analyzer
Applied Biosystems 3730xl DNA Analyzer
ABI SOLiD 4, 5500, 5500xl, 5500xl W Genetic Analyzers
Ion Torrent Personal Genome Machine (PGM)
Pacific Biosciences
PacBio RS
Technologies Under Development
Introduction
Human Microbiome Project Technology Development Awards
CHAPTER FOUR: SEQUENCING MARKET ANALYSIS
Revenues Forecast
Historical Revenues
Overall Market Forecast
Sequencing For a Clinical Purpose
Roche
ABI
Illumina
Affymetrix
B.C. Cancer Agency
Emory Genetics Lab
Bacterial and Viral Applications for NGS
eGenomics
BGI
Pacific Biosciences
Clinical Sequencing vs. Research Sequencing Markets
CHAPTER FIVE: COMPETITIVE ANALYSIS
Introduction
Benchtop and Third-Generation Sequencers Bring Instability
Second-, Third-Generation Battle Still Undefined, Unresolved
Increased Flexibility with Purchasing
ABI Capillary Electrophoresis Holds Onto Large Segment
DNA Sequencer Market Shares
Smaller Companies Experiencing Struggles
Features and Strengths of Second-Generation Sequencers
454 Life Sciences GS FLX–Strengths/Advantages
454 Life Sciences GS FLX–Weaknesses/Disadvantages
454 Life Sciences GS Junior–Strengths/Advantages
454 Life Sciences GS Junior–Weaknesses/Disadvantages
Applied Biosystems SOLiD–Strength/Advantages
Applied Biosystems SOLiD–Weaknesses/Disadvantages
Illumina HiSeq/HiScan SQ–Strength/Advantages
Illumina HiSeq/HiScan SQ–Weaknesses/Disadvantages
Illumina MiSeq - Strength/Advantages
Illumina MiSeq-Weaknesses/Disadvantages
Life Technologies PGM-Weaknesses/Disadvantages
Pacific Biosciences PacBio RS-Strength/Advantages
Pacific Biosciences PacBio RS-Weaknesses/Disadvantages
CHAPTER SIX: INTELLECTUAL PROPERTY AND LITIGATION
Developments
Helicos’ Patent Infringement Suit Against PacBio, Life Technologies, and Illumina
Intelligent Bio-Systems and Columbia University Sue Illumina for Infringement
Illumina’s Two Lawsuits Against Complete Genomics for Infringement
Illumina Sues Life Technologies Over Ion Torrent Systems
Class Action Shareholder Lawsuit Filed Against Pacific Biosciences
Affymetrix Dismisses Suit Against Pacific Biosciences and Former Employees
Life Technologies Defeats VisiGen Stakeholders After Arbitration
Catalyst Assets Sues Life Technologies for Infringement
Patent Interference Between Life Technologies and Pacific Biosciences
Life Technologies and Illumina Dispute Over Amplification on Solid Surfaces
LadaTech Sues Illumina Over DNA Amplification Patent
Illumina Files ‘841 Patent Infringement Suit Against Affymetrix
Affymetrix and Illumina Settle Case Over ‘243, ‘432, ‘531, ‘365, and ‘716
Applied Biosystems and Illumina Claims and Counter-claims Over Sequencing-by-Ligation Both Unsuccessful
Fluidigm and Applied Biosystems Agree to End Case
Beckman Coulter and Applied Biosystems Settle Outstanding Legal Disputes
Cepheid and Idaho Technology Settle Dispute Over PCR Patents
Enzo Biochem Disputes CalTech Sequencing Patents
Huang v. CalTech
Applied Biosystems and Amersham plc (GE Healthcare) Settle Sequencing Patent Litigation
Early ABI (Life Technologies) Patents
CHAPTER SEVEN: DEALS
List of Deals in the Sequencing Industry
CHAPTER EIGHT: CORPORATE PROFILES
454 Life Sciences (Roche)
Complete Genomics
Illumina
Life Technologies
Pacific Biosciences
CHAPTER NINE: CHALLENGES AND STRATEGIC RECOMMENDATIONS
Market Challenges
Fragmentation of Market Complicates Competition
Lower System Prices and Higher Output Restrain Revenues
Market Slowed by Data Analysis and Interpretation Bottleneck
Clinical Applications Present Range of Requirements and Challenges
Threat of New Entrants Despite Increasing Barrier
Potential for Saturation in High-End Segments
Services Experiencing High Growth, But Eating Into Tools Companies’ Revenues
Pharmacogenomics, Personal and Consumer Genomics Slowed by Regulatory and Medical Dogma
Biases at Multiple Levels Raise Issues of Standards, Quality Metrics
Strategic Recommendations
Intense Competition Requires Constant Innovation
Balance Risks by Diversifying
Prepare for Applications Opened by Decreasing Cost
Address Growing International Demand
Create User-Friendliness Through Tailored Software Tools
Increase Value by Combining with Complementary Technology or Content
Explore Demand in Expanding Routine Industry Segments
Establish Early Connections With End-Users
Move Towards Diagnostic Environment Requires Partnering
Introduction
New Systems, Services Create Uncertainty
A Period of Rapid Adoption, But Lower Prices
Further Longer-Term Challenges
Rapid Growth Overall, But Intense Competition
Customers’ Research Models Evolving
Established Next-Generation Systems Seeing Slowdown
Background
Scope and Methodology
Applications and Definitions
Types of Samples
DNA Sequencing Strategies
CHAPTER TWO: SEQUENCER MARKET TRENDS
Industry and Technology Trends
Market Fragmenting Into Multiple Product Types and Applications
Continual Improvements Expand Sequencer Market
Acquisitions and Collaborations for New Technologies
Patent Infringement, Other Legal Disputes
Slow Path to Potentially Large Clinical Markets
Spread of Targeted Enrichment, Sequence-Capture Products and Services
Synergies Appearing Between Life Science Companies’ Products
Consumer Genomics, Genetic Testing, Pharmacogenetics Still Entering Mainstream
NHGRI Funding, Budget, Periodic Strategic Planning
NHGRI Shifts Funds from Centralized Sequencing Centers
NHGRI White Paper #4: The Future of Genome Sequencing
Genome Projects and Consortia
The Cancer Genome Atlas (TCGA) Project
National Plant Genome Initiative
NSF/USDA Microbial Genome Sequencing Program
CHAPTER THREE: DNA SEQUENCING SYSTEMS AND TECHNOLOGIES
454 Life Sciences (Roche)
Genome Sequencer FLX, FLX+, Junior
Illumina
HiSeq, HiScan SQ, MiSeq, Genome Analyzer IIx
Intelligent Biosystems (Qiagen)/Azco Biotech
LI-COR Biosciences 4300
Life Technologies/Applied Biosystems
ABI Prism 310 Genetic Analyzer
ABI Prism 3100-Avant Genetic Analyzer
Applied Biosystems 3100 Genetic Analyzer
Applied Biosystems 3130 Genetic Analyzer
Applied Biosystems 3130xl Genetic Analyzer
Applied Biosystems 3500 Genetic Analyzer
Applied Biosystems 3730 DNA Analyzer
Applied Biosystems 3730xl DNA Analyzer
ABI SOLiD 4, 5500, 5500xl, 5500xl W Genetic Analyzers
Ion Torrent Personal Genome Machine (PGM)
Pacific Biosciences
PacBio RS
Technologies Under Development
Introduction
Human Microbiome Project Technology Development Awards
CHAPTER FOUR: SEQUENCING MARKET ANALYSIS
Revenues Forecast
Historical Revenues
Overall Market Forecast
Sequencing For a Clinical Purpose
Roche
ABI
Illumina
Affymetrix
B.C. Cancer Agency
Emory Genetics Lab
Bacterial and Viral Applications for NGS
eGenomics
BGI
Pacific Biosciences
Clinical Sequencing vs. Research Sequencing Markets
CHAPTER FIVE: COMPETITIVE ANALYSIS
Introduction
Benchtop and Third-Generation Sequencers Bring Instability
Second-, Third-Generation Battle Still Undefined, Unresolved
Increased Flexibility with Purchasing
ABI Capillary Electrophoresis Holds Onto Large Segment
DNA Sequencer Market Shares
Smaller Companies Experiencing Struggles
Features and Strengths of Second-Generation Sequencers
454 Life Sciences GS FLX–Strengths/Advantages
454 Life Sciences GS FLX–Weaknesses/Disadvantages
454 Life Sciences GS Junior–Strengths/Advantages
454 Life Sciences GS Junior–Weaknesses/Disadvantages
Applied Biosystems SOLiD–Strength/Advantages
Applied Biosystems SOLiD–Weaknesses/Disadvantages
Illumina HiSeq/HiScan SQ–Strength/Advantages
Illumina HiSeq/HiScan SQ–Weaknesses/Disadvantages
Illumina MiSeq - Strength/Advantages
Illumina MiSeq-Weaknesses/Disadvantages
Life Technologies PGM-Weaknesses/Disadvantages
Pacific Biosciences PacBio RS-Strength/Advantages
Pacific Biosciences PacBio RS-Weaknesses/Disadvantages
CHAPTER SIX: INTELLECTUAL PROPERTY AND LITIGATION
Developments
Helicos’ Patent Infringement Suit Against PacBio, Life Technologies, and Illumina
Intelligent Bio-Systems and Columbia University Sue Illumina for Infringement
Illumina’s Two Lawsuits Against Complete Genomics for Infringement
Illumina Sues Life Technologies Over Ion Torrent Systems
Class Action Shareholder Lawsuit Filed Against Pacific Biosciences
Affymetrix Dismisses Suit Against Pacific Biosciences and Former Employees
Life Technologies Defeats VisiGen Stakeholders After Arbitration
Catalyst Assets Sues Life Technologies for Infringement
Patent Interference Between Life Technologies and Pacific Biosciences
Life Technologies and Illumina Dispute Over Amplification on Solid Surfaces
LadaTech Sues Illumina Over DNA Amplification Patent
Illumina Files ‘841 Patent Infringement Suit Against Affymetrix
Affymetrix and Illumina Settle Case Over ‘243, ‘432, ‘531, ‘365, and ‘716
Applied Biosystems and Illumina Claims and Counter-claims Over Sequencing-by-Ligation Both Unsuccessful
Fluidigm and Applied Biosystems Agree to End Case
Beckman Coulter and Applied Biosystems Settle Outstanding Legal Disputes
Cepheid and Idaho Technology Settle Dispute Over PCR Patents
Enzo Biochem Disputes CalTech Sequencing Patents
Huang v. CalTech
Applied Biosystems and Amersham plc (GE Healthcare) Settle Sequencing Patent Litigation
Early ABI (Life Technologies) Patents
CHAPTER SEVEN: DEALS
List of Deals in the Sequencing Industry
CHAPTER EIGHT: CORPORATE PROFILES
454 Life Sciences (Roche)
Complete Genomics
Illumina
Life Technologies
Pacific Biosciences
CHAPTER NINE: CHALLENGES AND STRATEGIC RECOMMENDATIONS
Market Challenges
Fragmentation of Market Complicates Competition
Lower System Prices and Higher Output Restrain Revenues
Market Slowed by Data Analysis and Interpretation Bottleneck
Clinical Applications Present Range of Requirements and Challenges
Threat of New Entrants Despite Increasing Barrier
Potential for Saturation in High-End Segments
Services Experiencing High Growth, But Eating Into Tools Companies’ Revenues
Pharmacogenomics, Personal and Consumer Genomics Slowed by Regulatory and Medical Dogma
Biases at Multiple Levels Raise Issues of Standards, Quality Metrics
Strategic Recommendations
Intense Competition Requires Constant Innovation
Balance Risks by Diversifying
Prepare for Applications Opened by Decreasing Cost
Address Growing International Demand
Create User-Friendliness Through Tailored Software Tools
Increase Value by Combining with Complementary Technology or Content
Explore Demand in Expanding Routine Industry Segments
Establish Early Connections With End-Users
Move Towards Diagnostic Environment Requires Partnering
LIST OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Figure 1-1: DNA Sequencer Revenues, 2001-2011
CHAPTER TWO: SEQUENCER MARKET TRENDS
Table 2-1: NHGRI Budget by Year Including ARRA Supplement, 2006-2012
Figure 2-1: NHGRI Budget including ARRA (2006-2012)
Table 2-2: Est. NHGRI Budget by Mechanism, 2012 ($M)
Figure 2-2: NHGRI Budget
Table 2-3: NHGRI Budget by Activity, 2010-2012 ($thou)
Figure 2-3: NHGRI Budget by Activity, 2012
Table 2-4: NHGRI Funding, Large-Scale Sequencing Centers ‘07&’12
Figure 2-4: NHGRI Funding, Large-Scale Sequencing Centers ‘07&’12
Table 2-5: NHGRI Funding, Centers for Mendelian Genomics, 2012
Figure 2-5: NHGRI Funding, Centers for Mendelian Genomics, 2012
Table 2-6: NHGRI Clinical Sequencing Exploratory Research Awards, 2012
Table 2-7: Fuge Funding Recipients
Table 2-8: Plant Genome Comparative Sequencing Program (PGCSP) Awards, FY 2011
Table 2-9: NSF / USDA Microbial Genome Sequencing Program Awards, 2008-2011
Table 2-10 Other Initiatives and Consortia Using DNA Sequencing, 2012
CHAPTER THREE: DNA SEQUENCING SYSTEMS AND TECHNOLOGIES
Table 3-1: DNA Sequencer Products/ Technologies, 2012
Table 3-2: NIH Human Microbiome Project Technology Dev’t Awards, 2010
Table 3-3: NHGRI $1,000 Genome Grant Awards, 2009
Table 3-4: NHGRI $1,000 Genome Grant Awards, 2010
Table 3-5: NHGRI $1,000 Genome Grant Awards, 2011
Table 3-6: NHGRI Advanced Sequencing Technology Awardees, 2009
Table 3-7: NHGRI Medical Sequencing Discovery Awards, 2009
Table 3-8: NHGRI Understanding Genome Function Awards, 2009
Table 3-9: NHGRI Population Genomics Awards, 2009
Table 3-10: NHGRI Advanced Sequencing Technology Awardees, 2009
Table 3-11: Other Initiatives and Consortia Supporting Technology Development, 2012
CHAPTER FOUR: SEQUENCING MARKET ANALYSIS
Figure 4-1: Cost of Sequencing a Genome
Table 4-1: Market Forecast by Segment (Systems, Consumables, Services) , 2011-2016
Table 4-2: Sequencing Market Revenues Growth Rates by Segment, 2011-2016 (Systems, Consumables, Services)
Table 4-3: Sequencer Equipment Market, 2001-2011 ($M)
Table 4-4: Growth Rates, Sequencer Equipment Market, 2001-2011 ($M)
Figure 4-3: Sequencer Equipment Market, 2001-2011 ($M)
Figure 4-4: ABI Sequencing Revenues, Q3 2001 – Q3 2008
Figure 4-5: ABI Sequencing Revenues, Focus on Q4 2004 – Q3 2008
Figure 4-6: DNA Sequencer Market Forecast, 2011-2016:
Figure 4-7: Breakout of DNA Sequencing Market by Application(Clinical vs. Research) 2011
Figure 4-8: Breakout of DNA Sequencing Market by Application(Clinical vs. Research) 2016
CHAPTER FIVE: COMPETITIVE ANALYSIS
Table 5-1: DNA Sequencer Market Shares
Figure 5-1: DNA Sequencer Market Shares
Figure 5-2: Pacific Biosciences Quarterly Revenues, 2011-2012 ($M)
Figure 5-3: Complete Genomics Quarterly Revenues, 2010-2012 ($M)
Table 5-2 Comparison of Sequencers’ Performance, mid-2012
CHAPTER SIX: INTELLECTUAL PROPERTY AND LITIGATION
Table 6-1: Patents
CHAPTER SEVEN: DEALS
Table 7-1: Deals in the Sequencer Market
CHAPTER ONE: EXECUTIVE SUMMARY
Figure 1-1: DNA Sequencer Revenues, 2001-2011
CHAPTER TWO: SEQUENCER MARKET TRENDS
Table 2-1: NHGRI Budget by Year Including ARRA Supplement, 2006-2012
Figure 2-1: NHGRI Budget including ARRA (2006-2012)
Table 2-2: Est. NHGRI Budget by Mechanism, 2012 ($M)
Figure 2-2: NHGRI Budget
Table 2-3: NHGRI Budget by Activity, 2010-2012 ($thou)
Figure 2-3: NHGRI Budget by Activity, 2012
Table 2-4: NHGRI Funding, Large-Scale Sequencing Centers ‘07&’12
Figure 2-4: NHGRI Funding, Large-Scale Sequencing Centers ‘07&’12
Table 2-5: NHGRI Funding, Centers for Mendelian Genomics, 2012
Figure 2-5: NHGRI Funding, Centers for Mendelian Genomics, 2012
Table 2-6: NHGRI Clinical Sequencing Exploratory Research Awards, 2012
Table 2-7: Fuge Funding Recipients
Table 2-8: Plant Genome Comparative Sequencing Program (PGCSP) Awards, FY 2011
Table 2-9: NSF / USDA Microbial Genome Sequencing Program Awards, 2008-2011
Table 2-10 Other Initiatives and Consortia Using DNA Sequencing, 2012
CHAPTER THREE: DNA SEQUENCING SYSTEMS AND TECHNOLOGIES
Table 3-1: DNA Sequencer Products/ Technologies, 2012
Table 3-2: NIH Human Microbiome Project Technology Dev’t Awards, 2010
Table 3-3: NHGRI $1,000 Genome Grant Awards, 2009
Table 3-4: NHGRI $1,000 Genome Grant Awards, 2010
Table 3-5: NHGRI $1,000 Genome Grant Awards, 2011
Table 3-6: NHGRI Advanced Sequencing Technology Awardees, 2009
Table 3-7: NHGRI Medical Sequencing Discovery Awards, 2009
Table 3-8: NHGRI Understanding Genome Function Awards, 2009
Table 3-9: NHGRI Population Genomics Awards, 2009
Table 3-10: NHGRI Advanced Sequencing Technology Awardees, 2009
Table 3-11: Other Initiatives and Consortia Supporting Technology Development, 2012
CHAPTER FOUR: SEQUENCING MARKET ANALYSIS
Figure 4-1: Cost of Sequencing a Genome
Table 4-1: Market Forecast by Segment (Systems, Consumables, Services) , 2011-2016
Table 4-2: Sequencing Market Revenues Growth Rates by Segment, 2011-2016 (Systems, Consumables, Services)
Table 4-3: Sequencer Equipment Market, 2001-2011 ($M)
Table 4-4: Growth Rates, Sequencer Equipment Market, 2001-2011 ($M)
Figure 4-3: Sequencer Equipment Market, 2001-2011 ($M)
Figure 4-4: ABI Sequencing Revenues, Q3 2001 – Q3 2008
Figure 4-5: ABI Sequencing Revenues, Focus on Q4 2004 – Q3 2008
Figure 4-6: DNA Sequencer Market Forecast, 2011-2016:
Figure 4-7: Breakout of DNA Sequencing Market by Application(Clinical vs. Research) 2011
Figure 4-8: Breakout of DNA Sequencing Market by Application(Clinical vs. Research) 2016
CHAPTER FIVE: COMPETITIVE ANALYSIS
Table 5-1: DNA Sequencer Market Shares
Figure 5-1: DNA Sequencer Market Shares
Figure 5-2: Pacific Biosciences Quarterly Revenues, 2011-2012 ($M)
Figure 5-3: Complete Genomics Quarterly Revenues, 2010-2012 ($M)
Table 5-2 Comparison of Sequencers’ Performance, mid-2012
CHAPTER SIX: INTELLECTUAL PROPERTY AND LITIGATION
Table 6-1: Patents
CHAPTER SEVEN: DEALS
Table 7-1: Deals in the Sequencer Market
